MyFinsight
Home
Blog
About
Contact
Cash and cash
equivalents
$156,158K
Accounts receivable, net
$132,352K
Inventories, net
$104,209K
Prepaid inventory costs
$54,928K
Other prepaid and
current assets
$6,023K
Prepaid clinical
development costs
$5,791K
Total current assets
$459,461K
Right of use operating
lease assets
$2,701K
Property and equipment,
net
$311K
Intangible assets
$56K
Total assets
$462,529K
Accumulated deficit
-$1,648,907K
Treasury stock, at cost
1,994,198 shares at...
$54,998K
Total liabilities and
stockholders deficit
$462,529K
Total stockholders
deficit
-$307,931K
Additional paid-in capital
$1,395,717K
Common stock, 0.001 par
value 480,000,000...
$257K
Total liabilities
$770,460K
Total current
liabilities
$300,359K
Royalty sale liability
$210,433K
Long-term debt
$152,674K
Convertible notes, net of
issuance costs
$97,394K
Other long-term
liabilities
$8,739K
Operating lease
liabilities
$861K
Accrued variable
consideration
$85,811K
Royalty sale liability
$80,746K
Accounts payable
$68,406K
Deferred revenue from
collaborations
$43,531K
Other accrued
liabilities
$17,489K
Accrued clinical
development costs
$2,677K
Operating lease
liabilities
$1,699K
Back
Back
Balance Sheet
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)
source: myfinsight.com